PLD2

Across TCGA pan-cancer cohorts, PLD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLD2 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, GBM, and PDAC are the cancer types where PLD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	1.000	0.344	.009	23	view →
GBM	OS	Median	All	0.753	0.873	.010	6	view →
PDAC	DFS	Median	III,IV	0.256	0.739	.005	5	view →
CCRCC	OS	Median	All	1.000	0.930	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLD2–HNSC (OS)

Open the HNSC breakdown →